Abcam, ab288440, Anti-IRF7 antibody [EPR25274-33]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal IRF7 antibody. Suitable for WB and reacts with Mouse samples. Cited in 2 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR25274-33,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The transcription factor IRF7 also known as Interferon Regulatory Factor 7 plays a significant role in the regulation of type I interferon genes. This protein acts as an important modulator of the immune response specifically during viral infections. The molecular weight of IRF7 is approximately 54 kDa. It is predominantly expressed in lymphoid tissues such as the spleen and thymus and is also found in other immune cells like B cells and dendritic cells. The expression of IRF7 is induced by pathogen-associated molecular patterns which stimulate the activation of immune signaling pathways.
Biological function summary
IRF7 activates and modulates the expression of type I interferons and other cytokines important for antiviral defense. This protein can form part of a larger complex with other IRF family members to enhance its effect on gene transcription. IRF7 operates through its interaction with transcriptional coactivators allowing it to execute its function as a transcriptional activator reinforcing the immune system's response to infectious agents.
Pathways
IRF7 plays a critical role in the Toll-like receptor (TLR) signaling pathway and retinoic acid-inducible gene I (RIG-I) pathway. It directly interacts with MyD88 and IRAK1 proteins linking it to signal transduction pathways that lead to interferon-beta production. The activation of IRF7 in these pathways also strengthens the body's defense mechanism by enhancing the transcription of antiviral genes forming a robust antibacterial and antiviral environment within the host.
IRF7's function is implicated in autoimmune diseases and specific cancers. For autoimmune conditions like systemic lupus erythematosus (SLE) dysregulated IRF7 activity is observed leading to an aberrant interferon response. It connects with proteins such as IRF5 which has its expressions elevated in affected patients. In relation to cancer IRF7 can impact tumor progression particularly in breast cancer through modulation of immune surveillance functions. Its interaction with interferon pathways becomes a double-edged sword affecting tumor immunity and progression.